21:04 , Jan 15, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer In vitro , patient sample, cell culture and rat studies identified an inhibitor of thrombin-mediated PAR1 activation that could help treat glioblastoma. In tumor samples from patients, PAR1 expression was higher than...
07:00 , Sep 15, 2016 |  BC Innovations  |  Targets & Mechanisms

KOR-recting MS

Although the failed Phase II multiple sclerosis trial of Biogen Inc. 's anti-LINGO mAb in June dealt a blow to myelin repair, a slew of compounds acting by different mechanisms lies behind it in clinical...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Company News

Merck, Aralez deal

Aralez purchased U.S. and Canadian rights to Zontivity vorapaxar from Merck. The protease-activated receptor 1 (PAR1) antagonist that inhibits thrombin-induced platelet activation is approved to reduce thrombotic cardiovascular events in patients with a history of...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Company News

Merck sales and marketing update

Merck said it will discontinue marketing Zontivity vorapaxar in the U.S., effective Sept. 2. Merck said the decision was for “business reasons” and not related to safety and efficacy of Zontivity. As a result of...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

Zontivity vorapaxar regulatory update

EMA’s CHMP recommended expanding the label of Zontivity vorapaxar from Merck to include reduction of atherothrombotic events in adults with symptomatic peripheral arterial disease (PAD). The protease-activated receptor 1 (PAR1) antagonist that inhibits thrombin-induced platelet...
07:00 , Aug 27, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Atomic force microscopy (AFM) for measuring GPCR-ligand binding in lipid membranes

Assays and screens TECHNOLOGY: Binding assays An AFM-based method could measure binding affinities between ligands and GPCRs in lipid membranes. The method involves attaching a GPCR ligand to the tip of an oscillating cantilever moving...
08:00 , Mar 2, 2015 |  BC Week In Review  |  Clinical News

Zontivity vorapaxar: Additional Phase III data

Additional data from 3,623 patients with diabetes mellitus and a prior MI and without a history of stroke or transient ischemic attack in the double-blind Phase III TRA 2P-TIMI 50 trial showed that Zontivity vorapaxar...
08:00 , Dec 4, 2014 |  BC Innovations  |  Cover Story

GPCRs' grand plans

In a move to expand tenfold the number of known 3D structures of the highly druggable class of GPCRs, Amgen Inc. , Ono Pharmaceutical Co. Ltd. and Sanofi have teamed up with three academic organizations...
07:00 , May 12, 2014 |  BC Week In Review  |  Clinical News

Zontivity vorapaxar regulatory update

FDA approved an NDA for Zontivity vorapaxar from Merck to reduce thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). The label says the drug has...
07:00 , May 12, 2014 |  BioCentury  |  Strategy

Good news for dealmakers

While Merck & Co. Inc. continues its stepwise downsizing, the pharma is sending signals that the welcome mat is out for BD&L deals. The pharma made good on its plan to seek alternatives for its...